Cancer Research: Funding Gap

Debate between Viscount Camrose and Lord Hunt of Kings Heath

Monday 29th January 2024 Lords Chamber

[Lord Hunt of Kings Heath]

To ask His Majesty’s Government what assessment they have made of the analysis by Cancer Research UK projecting a £1 billion funding gap for cancer research.

[The Parliamentary Under-Secretary of State, Department for Science, Innovation and Technology (Viscount Camrose) (Con)]

The Government remain fully committed to tackling cancer by investing in cutting-edge cancer research. We invested almost £122 million into cancer research in 2022-23 via the National Institute for Health and Care Research, while UK Research and Innovation invests around £200 million annually. We work closely with research funders, industry, the NHS and charities to drive earlier diagnosis and improved therapies. We are confident that the Government’s unwavering commitment will lead to continued improvements for cancer patients.

[Lord Hunt of Kings Heath (Lab)]

My Lords, I am grateful to the Minister, particularly in relation to his final comment about long-term investment. He will be aware that around 62% of all publicly funded research on cancer comes from the charitable sector. The last few years have been incredibly tough for the sector in raising money. As an example, over the past five years Cancer Research UK has seen a 19% drop in real terms in the amount it can invest in cancer research. It argues that we are in danger of losing about £1 billion of investment into cancer research over the next ten years, and has called for a commission on sustainable biomedical research task force to look at how government, the charitable sector and other funders can collectively fill that gap. Are the Government sympathetic to that?

[Viscount Camrose (Con)]

Yes, entirely, and I thank the noble Lord for raising this very important issue. I pay tribute to the very important and good work done by Cancer Research UK. If its analysis—I am familiar with its basic thrust—has a flaw, it is that it makes an assumption about an ongoing linear link between the number of cancer sufferers over the year and direct government and charity sector support. This assumption neglects to bring in, first, the close work done between the Government, businesses—through business co-funding—and others, and, secondly, the growing, extensive, important research that is relevant to cancer but not specifically associated with it. In particular, many of us are familiar with the work done on radiology in AI. It is not cancer-specific but is certainly likely to help the cause of improving cancer outcomes.